AbbVie Inc. $ABBV Shares Purchased by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. raised its position in AbbVie Inc. (NYSE:ABBV) by 96.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 256,599 shares of the company’s stock after buying an additional 126,024 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in AbbVie were worth $59,413,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ABBV. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the 2nd quarter valued at about $36,000. Bear Mountain Capital Inc. lifted its stake in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares in the last quarter. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $213.90 on Wednesday. The stock has a market capitalization of $378.04 billion, a price-to-earnings ratio of 162.05, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. The business has a 50-day moving average of $226.50 and a 200 day moving average of $216.99. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Analyst Ratings Changes

Several research firms recently commented on ABBV. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research note on Monday, November 3rd. Finally, Morgan Stanley increased their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.